Bank of America’s Edesa Biotech EDSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-52
Closed -$74 6060
2025
Q4
$74 Buy
52
+1
+2% +$2 ﹤0.01% 6882
2025
Q3
$126 Sell
51
-3
-6% -$7 ﹤0.01% 7808
2025
Q2
$109 Buy
54
+32
+145% +$68 ﹤0.01% 7953
2025
Q1
$54 Buy
22
+3
+16% +$6 ﹤0.01% 7966
2024
Q4
$32 Hold
19
﹤0.01% 7938
2024
Q3
$85 Buy
19
+1
+6% +$5 ﹤0.01% 7745
2024
Q2
$77 Buy
+18
New +$80 ﹤0.01% 7760
2022
Q1
Sell
-2
Closed 8370
2021
Q4
$0 Buy
+2
New +$96 ﹤0.01% 8315
2021
Q3
Sell
-7
Closed 8168
2021
Q2
$0 Buy
+7
New +$284 ﹤0.01% 7820
2020
Q3
Sell
-2
Closed 6953
2020
Q2
$0 Sell
2
-44
-96% -$991 ﹤0.01% 6899
2020
Q1
$1K Buy
+46
New +$946 ﹤0.01% 6704
2019
Q4
Sell
-1
Closed 7152
2019
Q3
$0 Buy
+1
New +$36 ﹤0.01% 7303
2019
Q1
Hold
0
7175
2018
Q4
Hold
0
7167
2018
Q3
Sell
-2
Closed -$127 7307
2018
Q2
$0 Hold
2
﹤0.01% 7129
2018
Q1
$0 Hold
2
﹤0.01% 7146
2017
Q4
$0 Hold
2
﹤0.01% 7067
2017
Q3
$1K Hold
2
﹤0.01% 6923
2017
Q2
$1K Hold
2
﹤0.01% 6806
2017
Q1
$1K Hold
2
﹤0.01% 6845
2016
Q4
$1K Hold
2
﹤0.01% 6895
2016
Q3
$1K Sell
2
-1
-33% -$839 ﹤0.01% 6923
2016
Q2
$3K Buy
3
+1
+50% +$1.03K ﹤0.01% 6797
2016
Q1
$2K Hold
2
﹤0.01% 6770
2015
Q4
$3K Buy
+2
New +$4.64K ﹤0.01% 7009

Other funds holding EDSA

Bank of America's EDSA Position: Q1 2026 in Review

Bank of America sold out of Edesa Biotech (EDSA) in Q1 2026, closing a stake of 52 shares — an estimated $74 sold.

Bank of America first reported a position in EDSA in Q4 2015 and held it in 23 quarters. The position peaked at $3K in Q2 2016. 28 funds tracked by Wall St. Rank hold EDSA as of Q1 2026.

  • Bank of America reported no remaining Edesa Biotech position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 52 Edesa Biotech shares in Q1 2026, an estimated $74.
  • Bank of America first reported a position in Edesa Biotech in Q4 2015 and held it in 23 quarters.
  • Bank of America's Edesa Biotech position peaked at $3K in Q2 2016.
  • 28 funds tracked by Wall St. Rank held Edesa Biotech as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.